![]() SLNB was carried out according to Morton’s protocol (1). Tumour thickness (mm), differentiation, perineural invasion and diameter (cm) were recorded. If the SLNB showed histological evidence of micro-metastases, radical lymph node dissection (RLND) of the involved basins was recommended.įor each patient, primary tumours were diagnosed histologically using haematoxylin and eosin (H&E) staining. For T1 and T3 tumours, staged according to AJCC guidelines (7), the decision to undergo SLNB was made individually after decision of the MTB. Main indication of SLNB procedure was patients with T2 (AJCC 7 th edition (7)) tumours. In our centre, SLNB procedures were offered to patients with unique cSCC TxN0M0 profiles. Patients were selected from the Multidisciplinary Tumour Board (MTB) list, in which all patients with cSCC are reported, and cross-referenced with the list of all those who underwent a sentinel lymph node biopsy (SLNB). Patients were selected from the cohort of cutaneous cell carcinoma (cSCC) patients treated at the Saint Louis Hospital (Paris, France) between January 2008 and March 2014 and were followed until September 2016. The aim of this study was to evaluate the benefits of SLNB and the impact of SLNB results on progression and death in cSCC. However, the exact impact of SLNBs on cSCC remains unclear and controversial, and the procedure can result in overtreatment and higher morbidity for low-progression patients. SLNB was therefore proposed to complete the staging procedure for cSSC. SLNB efficiency was analysed in a large study ( n = 847) of SCC cases in the oral cavity and oropharynx, with positive SLNB results observed in 18–60% of patients with high sensitivity (93%) (9, 10). Risk factors (size, thickness and invasion beyond the fat, perineural invasion, poor differentiation, head and neck location, immunosuppression) (4–6) and tumour-node-metastasis (TNM) classifications (7, 8) have been proposed to evaluate tumour prognosis. ![]() Early diagnosis of nodal metastasis, which is the primary progression route for cSCC, is a major goal for dermatologists and oncologists, in order to optimize the care of these patients. Although mortality in cSCC is lower than in melanoma or Merkel cell carcinoma, cSCC is associated with local recurrence (4.6%), node metastasis (3.7%) and distant metastasis leading to patient death (2.1%) (5). However, due to lack of evidence, SLNB is not currently recommended by a European consensus for use in cutaneous squamous cell carcinoma (cSCC), which is a frequent and potentially aggressive skin tumour (4). In dermatology, SLNB is recommended for the most frequent aggressive cutaneous neoplasms, such as melanoma (1, 2) and Merkel cell carcinoma (3). S entinel lymph node biopsy (SLNB) is a common procedure for improving initial staging in oncology.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |